

## PERSONAL INFORMATION

Francesca Rossi



📍 University of Campania Luigi Vanvitelli  
Department of Woman, Child and of General and Specialist Surgery  
Via Luigi De Crecchio, 4, Naples, Italy

📞 +39 0815665342 📞 +39 3358184429

✉️ [francesca.rossi@unicampania.it](mailto:francesca.rossi@unicampania.it)

Sex Female | Date of birth 07/08/1976 | Nationality Italian

## WORK EXPERIENCE

From 2020 to date

### Full Professor in Pediatrics

Department of Woman, Child and of General and Specialist Surgery, University of Campania Luigi Vanvitelli

Teaching activity in PHD, Master's Degree Course, Bachelor's Degree Course, School of Specialization  
Head of the research group "Pediatric Onco-Hematology" (<https://www.dipdbc.unicampania.it/>)

Department Referent for: Research Quality, Research Activities, Third Mission Activities, VQR Procedure, IRIS database, SUA-RD (<https://www.dipdbc.unicampania.it/>)

From 2015 to 2020

### Associate Professor in Pediatrics

Department of Woman, Child and of General and Specialist Surgery, University of Campania Luigi Vanvitelli

Teaching activity in PHD, Master's Degree Course, Bachelor's Degree Course, School of Specialization  
Head of IPAS "Haematological Diseases of Paediatric Interest" (<https://www.policliniconapoli.it>)

From 2004-2015

### Researcher

Department of Woman, Child and of General and Specialist Surgery, Second University of Naples, Italy.

Translational activity with the main focus on Pediatric Hematological Diseases and Cancer

From 2010 to 2013

### PI of clinical and research program "Strategie per l'ottimizzazione del trapianto aploidentico in pazienti pediatrici"

Department of Onco-haematology and Transfusion Medicine, Bambino Gesù Hospital, Rome, Italy

Scientific activity Coordinator

From October to December 2009

### Clinical and Research Activity

Department of Pediatric Onco-hematology "Policlinico San Matteo, Pavia, Italy

From January to April 2006

### Research Activity

Department of Internal Medicine (Granelli section) - Faculty of Medicine and Surgery, University of Milan, Italy

## EDUCATION AND TRAINING

October 2005

### Specialization Degree in Pediatrics (5 years)

50/50 cum laude

Faculty of Medicine and Surgery, Second University of Naples, Italy.

Management of physical, emotional and social health of children from birth to young adulthood

2004

### Fellowship

Department of Pediatric Onco-hematology Policlinico San Matteo Pavia, Italy

Clinical practice on hematopoietic stem cells transplantation in paediatric diseases

2002

### Fellowship

Sbarro Institute for Cancer Research and Molecular Medicine - Temple University - Philadelphia, USA

Cellular and molecular biology

July 2000

### Graduation Degree in Medicine (6 years)

110/110 cum laude

Medical School, Second University of Naples, Italy

## WORK ACTIVITIES

Awards

2013 Società Italiana di Farmacologia

2010 O.N.Da (Osservatorio Nazionale sulla Salute della Donna)

**Editorial activity**

Member of the Editorial Board of Pharmacological Research  
 Reviewer for PLOSone, Oncotarget, Scientific Reports, Current Drug Targets, Cancer Biomarkers, Paediatric Blood and Cancer  
 Guest Editor for the Special Issue "Frailty in Pediatric and Young Adult Cancer Survivors: From Bench to Bedside"-Cancers

**Invited presentations**

Invited speaker on topics related to "oncology and hematology" at numerous national meetings of the main scientific societies in the pediatric field, such as Società Italiana di Pediatria (SIP), Federazione Italiana Medici Pediatri (FIMP), Società Italiana di Pediatria Preventiva e Sociale (SIPPS).

**Grants**

- ✓ PRIN 2020 (Unit PI) Sirtuin-1 activation and antioxidant-based strategies for boosting exon-skipping efficiency in Duchenne Muscular Dystrophy: combination approach and nutraceutics in innovative pharmacotherapy"
- ✓ POR FESR Campania 2014-2020 Asse I "Ricerca e Innovazione" (Collaborator) Identification, Characterization and mining of colorectal tumorogenesis: cause, prevention & cure – iCURE
- ✓ PON I&C 2014-2020 MISE Agrifood 2019: (PI)"Identificazione di profili di rischio genomici, epigenomici e ambientali per malattie tumorali: efficacia e meccanismo d'azione di cibi bioattivi, micro e macronutrienti sul rischio di tumore (GOod Nutrition for Healthy life - GONHE)"
- ✓ VALERE 2019 (PI) "INflamm-aging related disorders in CHildrenCAncer Survivors".
- ✓ TAKEDA 2018 (PI) "Mifamurtide and TAM-like macrophages: anti-proliferative effect on osteosarcoma cells".
- ✓ FC Fellowships Call for Proposals 2017 (PI) "The role of CB2 receptor in the pathogenesis of celiac disease and associated bone loss"
- ✓ PRIN 2017 (Unit PI) "New pharmacological strategies modulating PGC1alpha signalling and mitochondrial biogenesis to restore skeletal and cardiac muscle functionality in Duchenne Muscular Dystrophy"
- ✓ AIL-Caserta 2017 (PI) "Nuovo target terapeutico per la Leucemia Linfoblastica Acuta -T dell'età pediatrica: il sistema Endocannabinoide/Endovanilloide"
- ✓ PRIN 2015 (Unit PI) "Neuroimmunoinflammazione nel dolore cronico: alterazioni sensoriali e cognitivo-comportamentali e nuove prospettive terapeutiche"
- ✓ Fondi Regione Campania Farmacovigilanza (2012-2014) (PI) "Valutazione della sicurezza dei farmaci utilizzati in onco-ematologia pediatrica attraverso identificazione degli eventi avversi correlati alle suddette terapie farmacologiche"
- ✓ 2007-2013 (Unit PI) M.O.V.I.E.- P.O.R. Campania FSE 2007-2013
- ✓ 2007-2013 (Unit PI) "Ruolo del sistema endocannabinoide/endovanilloide nelle cellule immuno-infiammatorie (hMSCs) di pazienti affetti da osteosarcoma: dalla patogenesi del tumore al dolore osseo ad esso associato". P.O.R. Campania FSE 2007-2013
- ✓ PRIN 2012 (Unit PI) "Nuovi target farmacologici per il trattamento del dolore cronico: coinvolgimento del sistema immuno-infiammatorio periferico e centrale"
- ✓ FIRB 2012 (Unit PI) "Ruolo della glia e delle cellule immuno-infiammatorie nel dolore cronico: individuazione di nuovi target farmacologici nell'analgésia e nella neuroinfiammazione periferica e centrale"
- ✓ PRIN 2008 (PI) "Osteoporosi e sistema cannabinoide/vanilloide: nuovi markers di malattia e nuovi target terapeutici"
- ✓ LEGGE 5 Regione Campania Annualità 2008 "Ruolo del sistema endocannabinoide/endovanilloide nel metabolismo osseo"
- ✓ AIFA 2007 (PI) "Studio clinico multicentrico prospettico controllato randomizzato in aperto sull'efficacia e la sicurezza del trattamento con Ig anti-D per via endovenosa in confronto con le Ig ev in bambini con porpora trombocitopenica immune cronica
- ✓ PRIN 2006 (Unit PI) "Recettore dell'eritropoietina e policitemia congenite e familiari: alterazioni genetiche e loro effetto sulla proliferazione e differenziamento dei precursori eritroidi"

**Clinical Trials**

AUO-Vanvitelli PI in the following international and national clinical trials:

- AIEOP-BFM ALL 2017: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted by the AIEOP-BFM study group
- EsPhALL2017/COGAALL1631:International phase 3 trial in Philadelphia chromosome-positive acutelymphoblastic leukemia (Ph+ ALL) testing imatinib in combinationwith two different cytotoxic chemotherapy backbones
- ICC AFL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia
- European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL): Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- IntReALL SR 2010: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group
- IntReALL HR 2010: International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group

- STUDIO OSSERVAZIONALE RETROSPETTIVO E PROSPETTICO AIEOP – LHPL(Linfoma di Hogkin a prevalenza linfocitaria)-2019
- AIEOP LAM 2013/01: protocollo per il trattamento della Leucemia Acuta Mieloide in età pediatrica

**Patents**

-2009-Patent: “Profarmacogalattosilato della n-omega-nitro-l-arginina (nagal) ad uso analgesico ed antinfiammatorio con migliori caratteristiche farmacocinetiche e di tollerabilità del farmaco di partenza”  
-2007-Patent: “2-FENIL-IMIDAZO[1,2-B]PIRIDAZINE AD ATTIVITÀ ANALGESICA ED ANTIEPILETTICA”

**ADDITIONAL INFORMATION**

**Publications**

Total number of publications in peer-review journals: 121; Total Impact Factor (IF): 685,62; Average IF/paper: 5.66  
Total number of citations: 3659; H index: 36

The complete list of Publication is available on **Scopus Author ID:** 35389583000

